Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Гормональный профиль у женщин в постменопаузе: нужна ли терапия андрогенами?

https://doi.org/10.33667/2078-5631-2019-1-1(376)-32-40

Полный текст:

Аннотация

Влияние андрогенов на здоровье женщины изучено недостаточно. У женщин в постменопаузе уровни циркулирующих тестостерона и дегидроэпиандростерона сульфата (ДГЭА-С) снижаются постепенно, тогда как во время менопаузального перехода наблюдаются их транзиторные подъемы. Считается, что высокий уровень тестостерона сопровождается повышенным риском развития рака молочной железы у женщин в постменопаузе. Гипоандрогения у женщин проявляется наличием пониженного уровня андрогенов в крови, приводит к сексуальным нарушениям, снижению либидо, депрессивному настроению, признакам и симптомам ограниченного действия андрогенов, таким как сниженная мышечная масса, сниженная плотность костей и пониженная оценка самочувствия.

Об авторе

Я. З. Зайдиева
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия


Список литературы

1. Randolph JF, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RD: Change in estradiol and follicle-stimulating hormone across the early menopausal transition: Effects of ethnicity and age. J Clin Endocrinol Metab 89: 1555-1561, 2004.

2. YasuiT, Uemura H, Irahara M, AraiM, Kojimahara N, Okabe R, Ishii Y, Tashiro S, Sato H: Differences in sensitivity to cold in Japanese men and postmenopausal women aged 50 years. Gender Medicine 4: 359-366, 2007.

3. Braunstein GD: Androgen insufficiency in women: summary of critical issues. Fertil Steril 77: S94-99, 2002.

4. Spencer JB, Klein M, Kumar A, Azziz R: The age-associated decline of androgens in reproductive age and menopausal black and white women. J Clin Endocrinol Metab 92:4730-4733,2007.

5. Khosla S, Melton III LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274, 1996.

6. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL: A prospective longitudinal study of serum testosterone, dehydroepiendrosterone sulfate and sex hormone binding globulin levels through the menopause transition. J Clin Endocrinol Metab 85:2832-2938,2000.

7. Sowers MFR, Zheng H, McConnell D, Nan B, Karvonen-Gutierrez CA, Randolph Jr JF: Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod 24: 2279-2285, 2009.

8. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N: Executive summary: Stages of reproductive aging workshop (STRAW). Fertil Steril 76: 874-878,2001.

9. Torrens JI, Sutton-Tyrrell K, Zhao X, Matthews K, Brockwell S, Sowers M, Santoro N: Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in mid-life women. Menopause 16:257-264,2009.

10. Crawford S, Santoro N, Laughlin GA, Sowers MF, McConnell D, Sutton-Tyrrell K, Weiss G, Vuga M, Randolph J, Lasley B: Circulating Dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab 94: 2945-2951, 2009.

11. Lasley BL, Crawford SL, Laughlin GA, Santoro N, McConnell DS, Crandall C, Greendale GA, Polotsky AJ, Vuga M: Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition. Menopause 18:494-498,2011.

12. Liu D, Dillon JS: Dehydroepiandrosterone activities endothelial cell nitric-oxide synthase by a specific plasma membrane receptor couple to Gi2,3. Bio Chem 2 77: 21379-21388, 2002.

13. West SL, D'Aloisio AA, Agans RP, Kalsbeck WD, Borisov NN, Thorp JM: Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med: 168: 1441-9,2008.

14. Rivera-Woll LM, Papalia M, Davis SR, Burger HG: Androgen insufficiency in women: diagnostic and therapeutic implications. Hum Reprod Update 10: 421-432, 2004.

15. Haren MT, Malmstrom TK, Banks WA, Patrick P, Miller DK, Morley JE: Lower serum DHEAS levels are associated with a higher degree of physical disability and depressive symptoms in middle-aged to older African American women. Maturitas 57: 347-360, 2007.

16. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, Korenman S, Lasley WL, Luborsky JL, McConnell D, Sowers MF, Weiss G: Correlates of circulating androgens in mid- life women: the study of women's health across the nation. J Clin Endocrinol Metab 90: 4836-45, 2005.

17. Bell RJ, Donath S, Davison SL, Davis SR: Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause 13: 65-71,2006.

18. Woods NF, Smith-Dijulio K, Percival DB, Tao EY, Mariella A, Mitchell ES. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause 15: 223-232, 2008.

19. Gallicchio L, Schilling C, Miller SR, Zacur H, Flaws JA. Correlates of depressive symptoms among women undergoing the menopausal transition. J Psychosom Res 63: 263-268, 2007.

20. Morsink LF, Vogelzangs N, Nicklas BJ, Beekman AT, Satterfield S, Rubin SM, Yaffe K, Simonsick E, Newman AB, Kritchevsky SB, Penninx BW; Health ABC Study. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC Study. Psychoneuroendocrinol 32: 874-883, 2007.

21. Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, Randolph JF Jr. Matthews KA: Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Arch Ben Psychiatry 67: 598-607, 2010.

22. Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A: Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 47: 685-691, 1999.

23. Berr C, Lafont S, Debuire B, Dartigues JF, Baulicu EE: Relationships of dehydroepiendrosterone sulfate in the elderly with functional, psychological, and mental status, and shortterm mortality: a French community-based study. Proc Natl Acad Sci USA 93: 13410-13415, 1996.

24. Rigaud AS, Pellerin J: Neuropsychic effects of dehydroeiandrosterone. Ann Med Interne 152 [Suppl 3]: IS43-49, 2001.

25. Wolf OT, Kirschbaum C: Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev 30:264-288, 1999.

26. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS: Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol 29:219-237,2008.

27. Hogervorst E, Matthews FE, Brayne C: Are optimal levels of testosterone associated with better cognitive function in healthy older women and men? Biophys Biochim Acta 1800: 1145-1152, 2010.

28. Thilers PP, MacDonald SW, Herlitz A: The association between endogenous free testosterone and cognitive performance: a populationbased study in 35 to 90-year-old men and women. Psychoneuroendocrinol 31: 565-576,2006.

29. Ryan J, Stanczyk FZ, Dennerstein L, Mack WJ, Clark MS, Szoeke C, Kildea D, Henderson VW: Hormone levels and cognitive function in postmenopausal midlife women. Neurobiol Aging: Dec 14. [Epub ahead of print], 2010.

30. Vallee M, Mayo W, Le Moal M: Role of pregnenolone, dehydroeiandrosterone and their sulfate esters on leaning and memory in cognitive aging. Brain Res Rev 37: 301-312, 2001.

31. Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, Schaub RT: DHEA-S plasma levels and incidence of Abheimer’s disease. Biol Psychiatr47:161-163,2000.

32. Karpf JM, Simon JA: The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 63:213-219,2009.

33. Riley A, Riley E: Controlled studies on women presenting with sexual disorders: I. Endocrine status. J Sex Marital Ther26:269-283,2000.

34. Guay AT: Decreased testosterone in regularly menstruating women with decreased libido: a clinical observation. J Sex Marital Ther27:513-519,2001.

35. Alarslan D, Sarandol A, Congiz C, Develioglu OH. Androgens and sexual dysfunction in naturally and surgically menopausal women. J Obstet Gynecol Res 37: 1027-1034, 2011.

36. Guay AT, Jacobson J: Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther 28, Supple 1: 129-142, 2002.

37. Turna B. Apaydin E, Semerci B, Altay B, Cikili N, Nazli O: Women with low libido: correlation of decreased androgen levels with female sexual function index. Intern J Impotence Res 17: 148-153, 2005.

38. Abu EO, Horner V, Kusec V, Triffitt JT, Compston JE: The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82: 3493-3497, 1997.

39. Davidson BJ, Ross RK, Paganini-Hill A, Hammond GD, Siiteri PK, Judd HL: Total and free estrogens and androgens in postmenopausal women with hip fractures. J Clin Endocrinol Metab 54: 115-120, 1982.

40. Cummings SR, Browner WS, Bauer DC, Stone K, Ensrud KE, Jamal S, Ettinger B: Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporosis Fractures Research Group. N Eng J Med 339:733-738, 1998.

41. Shelly JM, Green A, Smith AMA, Dudley E, Dennerstein L, Hopper J, Burger H: Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 8: 39-45, 1998.

42. Lambrinoudaki I, Christodoulakos G, Rizos D, Economou E, Argeitis J, Vlachou S, Creatsa M, Kouskouni E, Botsis D: Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 154: 907-16, 2006.

43. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, Buring JE: Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108: 1688-1693,2003.

44. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC, Lloyd-Jones D, Sowers MF, Torrens JI: Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the study of women across the nation (SWAN). Circulation 111: 1242-1249,2005.

45. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI: Association of endogenous sex hormones and insulin resistance among postmenopausal women: Results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 88: 1646-1652, 2003.

46. Lee CC, Kasa-Vubu JZ, Supiano MA: Androgenicity and obesity are independently associated wit insulin sensitivity in postmenopausal women. Metabolism 53: 507-512,2004.

47. Creatsa M, Armeni E, Stamatelopoulos K, Rizos D, Georgipoulos G, Kazani M, Alexandrou A, Dendrinos S, Augoulea A, Papamichael C, Lambrinoudaki I. Circulating androgen levels are associated with subclinicalatherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism 2011 [Epub ahead of print].

48. Barrett-ConnorE, Goodman-Gruen D: Dehydroepiandrosterone sulfate dose not predict cardiovascular death in postmenopausal women: The Rancho Bernardo Study. Circulation 91: 1757-1760, 1995.

49. Mazat L, Lafont S, Berr C, Debuire B, Tessier JF, Dartigues JF, Baulieu EE: Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA 98: 8145-8150,2001.

50. Osmanagaoglu MA, Okumus B, Osmanagaoglu T, Bozkaya H: The relationship between serum dehydroepiendrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women. J Women's Health 13: 993-999, 2004.

51. Trivedi DP, Khaw KT: Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 86: 4171-4177, 2001.

52. Yasui T, Uemura H, Irahara M, Arai M, Kojimahara N, Okabe R, Ishii Y, Tashiro S, Sato H: Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women. Clinica Chimica Acta 398:43-47,2008.

53. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo-Ueda Y, YagiS, Ikeda Y, Iwase T, Nishio S, Kawano H, Miki J, Yamada H, Hirata Y, Akaike M, Sata M, Matsumoto T. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis 212: 310-315, 2010.

54. Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, Azziz R, Braunstein GD, Pepine CJ, Bittner V, Vldo DA, Stanczyk FZ, Bairey Merz CN. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 95:4985-92,2010.

55. Casson PR, Toth MJ, Johnson JV, Stanczyk FZ, Casey CL, Dixon ME: Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women. J Clin Endocrinol Metab 95: 4276-4282, 2010.

56. Lippman M, Bolan G, Huff K: The effects of androgens and antiandrogens on hormoneresponsive human breast cancer in long-term tissue culture. Cancer Res 36: 4610-4618, 1976.

57. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88: 291-296, 1996.

58. Key T, Appleby P, Barnes I, Reeves G: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616,2 002.

59. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96: 1856-65,2004.

60. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiébaut A, Gonzalez CA, Quirôs JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, PalliD, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Endocr Relat Cancer 12: 1071-82,2005.

61. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P: Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 18:169-176,2009.

62. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosnet BA, Colditz GA, Hankinson SE: The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer 126: 199-207,2010.

63. Goldstat R. Briganti E, Tran J, Wolfe R, Davis SR: Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10: 390-398, 2003.

64. Nappi RE, Albani F, Santamaria V, Tonani S, Martini E, Terreno E, Brambilla E, PolattiF: Menopause and sexual desire: the role of testosterone. Menopause Int 16: 162-168, 2010.

65. Simon J, Braunstein G, Natchtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226-5233,2005.

66. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, WattsNB: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med 165: 1582-1589, 2005.

67. Davis SR. Moreau M. Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J; APHRODITE Study Team: Testosterone for low libido in postmenopausal women not taking estrogen. N Eng J Med 359: 2005-17, 2008.

68. Burger HG, Hailes J, Menelaus M. Nelson J, Hudson B, Balazs N: The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 6: 351-358, 1984.

69. Somboonporn W, Davis S, Seif M, Bell R: Testosterone for peri- and postmenopausal women. The Cochrane Database of Systematic Reviews 2005: 4 [article no: CD 004 509].

70. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J: A two year, double-blind comparison of estrogenandrogen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 44: 1012-1020, 1999.

71. Kocoska-Maras L, Zethraeus N, Radestad AF, Ellingsen T, von Schoultz B, Johannesson M, Hirschberg AL: A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertil Steril 95: 152-157, 2010.

72. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Coldidz GA: Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166: 1483-9, 2006.

73. Braunstein GD: Safety of testosterone treatment in postmenopausal women. Fertil Steril 88: 1-17, 2007.

74. Panzer C, Guay A: Testosterone replacement therapy in naturally and surgically menopausal women. J Sex Med 6: 8-18, 2009.

75. Shufelt CL, Braunstein GD: Safety of testosterone use in women. Maturitas 63: 63-66, 2009.

76. Buvat J: Androgen therapy with dehydroepiendrosterone. World J Urol 21: 346-355, 2003.

77. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L: Double blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatr 156: 646-649, 1999.

78. Cameron DR, Braunstein GD: The use of dehydroepiandrosterone therapy in clinical practice. Treat Endocrinol 4: 95-114,2005.

79. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 70: 22-25, 2911.

80. Weiderpass E Baron JA, Adami HO, Magnusson C, Lindgren A, Bergström R, Correia N, Persson I: Low-potency oestrogen and risk of endometrial cancer, a case-control study. Lancet29: 1824-8, 1999.

81. Nath A, Sitruk-Ware R: Different cardiovascular effects of progestins according to structure and activity. Climacteric 12 Suppl 1: 96-101, 2009.

82. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J: Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123: 933-41, 2008.

83. Bataille V, Perret B, Evans A, Amouyel P, Arveiler D, Ducimetiere P, Bard JM, Ferrieres J: Sex hormone-binding globulin is a major determinant of the lipid profile: the PRIME study. Atherosclerosis 179: 369-373, 2005.

84. Kupelian V, page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB: Low sex hormonebinding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850, 2006.

85. Mudai S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH: Endogenous postmenopausal hormones and serum lipids: The atherosclerosis risk in communities study. J Clin Endocrinol Metab 90: 1202-1209, 2005.

86. Preziosi P, Barrett-ConnorE, Papoz L, Roger M, Saint-Paul M, Nahoul K, Simon D: Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the telecom study. J Clin Endocrinol Metab 76:283-7, 1993.

87. Hajamor S, Despres JP, Couillard C, Lemieux S, Tremblay A, Prud'homme D, Tchernof A: Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome. Metabolism 52: 724-730,2003.

88. Yasui T, Tomita J, Miyatani Y, Yamada M, Uemura H, Irahara M, Arai M, Kojimahara N, Okabe R, IshiiY, Tashiro S, Sato H: Association of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clinica Chimica Acta 386: 69-75, 2007.

89. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Lilgron E, Schaison G: The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 86: 5060-5066,2001.

90. Davison SL, Bell R, Donath S, Montalto JG, Davis SR: Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 90: 3847-3853,2005.

91. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ: Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 92: 3040-3043, 2007.

92. McTiernan A, Wu L, Barnabei VM, Chen C, Hendrix S, Modugno F, Rohan T, Stanczyk FZ, Wang CY: Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108: 217-231, 2008.

93. Korse CM, Bonfrer JMG, van Beurden M, Verheijen RHM, Rookus MA: Estradiol and testosterone levels are lower after oophorectomy than after natural menopause. Tumor Biol 30: 37-42, 2009.

94. Endogenous Hormones and Breast Cancer Collaborative Group: Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. British J Cancer 105: 709-722, 2011.

95. Bui HN, Struys EA, Martens F, de Ronde W, Thienpont LM, Kenemans P, Verhoeven MO, Jakobs C, Dijstelbloem HM, Blankenstein MA: Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy. Ann Clin Biochem 47:248-252, 2010.

96. Alarslan D, Sarandol A, Cengiz C, Develioglu OH. Androgen and sexual dysfunction in naturally and surgically menopausal women. J Obstet Gynaecol Res 37: 1027-1034, 2011.

97. Demers LM: Androgen deficiency in women: role of accurate testosterone measurements. Maturitas 67: 39-45, 2010.

98. Barbieri RL: Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 166: 740-745, 1992.

99. Yasui T., Matsui S., Tani A., Kunimi K., Yamamoto S., Irahara M. Androgen in postmenopausal women.The Journal of Medical Investigation Vol. 59: 12-27, 2012.

100. Zhang X., Tworoger SS., Eliassen AH., Hankinson SE: Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137: 883-92, 2013.

101. Njjland E. A., Wejjmar Schultz W. C., Nathorst-Boos J. et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial // J. Sex Med. 2008. Vol. 5. P. 646-656.

102. Baber R.J, Panay N., Fenton A. Collaborative Group. International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health // IMS. Climacteric, 2016; 19, 109-150.


Для цитирования:


Зайдиева Я.З. Гормональный профиль у женщин в постменопаузе: нужна ли терапия андрогенами? Медицинский алфавит. 2019;1(1):32-40. https://doi.org/10.33667/2078-5631-2019-1-1(376)-32-40

For citation:


Zaydieva Y.Z. Hormonal profile in postmenopausal women: do they need androgen therapy? Medical alphabet. 2019;1(1):32-40. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-1(376)-32-40

Просмотров: 83


ISSN 2078-5631 (Print)